Navigation Links
A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients

ill be to pursue a larger Phase II study to optimize dosing regimens. Novo Nordisk A/S holds an exclusive license to the E1-I.N.T.(TM) product and can further develop and commercialize this product in accordance with the terms of the companies' amended license agreement as previously announced July 17, 2006.

In addition, these clinical data further support and validate the potential of Transition's other gastrin based therapies to provide type 2 diabetes patients with sustained improvement in glucose control. Transition holds the exclusive rights to a series of proprietary gastrin based combination therapies including GLP1-I.N.T.(TM) (a combination of gastrin analogue, G1, and a GLP-1 analogue) and combination therapies of gastrin and DPP-IV inhibitors. Based on these encouraging findings, Transition is accelerating the development of these combination gastrin-based therapies into clinical trials.

Conference Call Details:

Transition will host a conference call to be held at 5:00pm EST on Thursday, June 28th, 2007. Dr. Sherwyn Schwartz from San Antonio Texas who was the lead investigator in this study will be available to answer any questions. The conference call can be accessed by dialing 1 (800) 633-8548. International callers are advised to dial (212) 676-5241. To participate, please dial the conference number 15 minutes prior to the beginning of the call. A replay of the conference call will be available until July 6, 2007 by visiting Transition's website www.transitiontherapeutics.com.

About the Study Design

This exploratory Phase IIa clinical study for E1-I.N.T.(TM) was a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of daily E1-I.N.T.(TM) treatments for 4 weeks with a 6-month follow-up in type 2 diabetes patients. The E1-I.N.T.(TM) treatment consisted of a combination of two agents, G1 and E1. All patie
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
5. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
6. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
7. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
8. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
9. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
10. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
11. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
Post Your Comments:
(Date:3/2/2015)... -- Champions Oncology, Inc. (OTC-PINK: CSBR), a company engaged in ... personalize the development and use of oncology drugs, today ... convertible promissory notes with two of its executive officers ... David Sidransky , chairman of the board of ... and commitment of our two senior executives.  This note, ...
(Date:3/2/2015)... 2, 2015  Kush Bottles, North ... solutions for the marijuana industry, announced today that ... been nominated for a 2015 Excellence in Entrepreneurship ... Award is designed to recognize individuals who exemplify ... their creativity and determination, have established and nurtured ...
(Date:3/2/2015)... Ohio , March 2, 2015  Sarnova, ... the launch of the new www.tri-anim.com ... full-service, specialty healthcare distributor of respiratory, anesthesia and ... country. The site has many ... overall experience, making online shopping and ordering easier ...
Breaking Medicine Technology:Champions Oncology Extends Convertible Debt Financing 2Champions Oncology Extends Convertible Debt Financing 3Kush Bottles CEO, Nicholas Kovacevich, Nominated for 2015 "Excellence in Entrepreneurship Award" 2Tri-anim Health Services Launches New Website Featuring Improved Product Selection and Ease of Ordering 2Tri-anim Health Services Launches New Website Featuring Improved Product Selection and Ease of Ordering 3
... GNVC ) announced that Adel A.F. Mahmoud, M.D., ... the Company,s Board of Directors at its annual meeting of ... "Drs. Mahmoud and Connor bring a wealth of experience, especially ... expand the breadth and scope of our vaccine programs there ...
... June 22, 2011 Genesis Biopharma, Inc. (OTC/BB: GNBP), ... that it will hold a conference call with the ... Eastern (9:00 a.m. Pacific).  The Company,s Chairman and Chief ... on the business, and discuss the clinical and commercial ...
Cached Medicine Technology:GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors 2GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors 3GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors 4Genesis Biopharma to Hold Business Update Conference Call on June 29 2
(Date:3/2/2015)... Today the Brain Injury Association of America (BIAA) officially kicked ... support the more than 5.3 million Americans who are living ... nation in observing Brain Injury Awareness Month by conducting an ... the 2015 to 2017 campaign is: Not Alone. , ... general public about the incidence of brain injury and the ...
(Date:3/2/2015)... Market Publishers Ltd is extremely happy to offer ... Analysts Inc and recently added to its catalogue. , ... 2018, the global radiation therapy equipment market is poised ... suggests a holistic analysis of the situation in the ... covers the top market trends. The publication uncovers data ...
(Date:3/2/2015)... New York, New York (PRWEB) March 02, 2015 ... and Publisher of Idoll Magazine, a medium for the ... where patrons can find, and buy Mango, Passion Fruit, ... balms, Tuesday, March 3rd, 2015, after 1pm. , At ... Candy Cosmetics has recently came under fire by announcing ...
(Date:3/2/2015)... After a rigorous evaluation process that ... and long-term strategy, Blood Centers of America (BCA) has ... member centers’ testing needs. , BCA, which comprises more ... 30 percent of the U.S. blood supply, made the ... committed to drive cost savings to members,” said Bill ...
(Date:3/2/2015)... CA (PRWEB) March 02, 2015 ... that it has officially launched a multivitamin supplement ... head of product development for BNatrl, said the ... feedback from Olympic and other world-class athletes. , ... to use this pure whole food multivitamin to ...
Breaking Medicine News(10 mins):Health News:Brain Injury Association of America Launches “Not Alone” Campaign for Brain Injury Awareness Month 2Health News:New Topical Research Reports Prepared by GIA Now Available at MarketPublishers.com 2Health News:New Topical Research Reports Prepared by GIA Now Available at MarketPublishers.com 3Health News:Sex Sells! A Newly Minted Organic Bodycare Brand Courts Controversy at a Cost 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 3Health News:Bnatrl Launches Multivitamin Supplement for Runners 2
... and Updates on Key Discoveries, Plus Panel Discussion ... Internationally renowned physician-scientists will discuss the rapidly ... important recent discoveries in translational cancer research, during ... Foundation Clinical Investigator Symposium. The April ...
... States District Court for the District of Massachusetts has ... McKesson, a large drug wholesaler. The lawsuit, called ... DataBank, Inc., concerns the pricing of more than ... could get money back. Prescription ...
... Retain Decision Resources, Gold-Standard Status in 2017 for ... According to a New Report from Decision ResourcesWALTHAM, ... the world,s leading research and advisory firms for ... identify a therapy,s effect on mortality as the ...
... Hair Care collections are now available in the store,s ... International is proud to announce that its natural hair ... shop, which features the best in natural and organic ... Lamas Naturals collection, which includes shampoos, conditioners, and styling ...
... dosages , , THURSDAY, April 23 (HealthDay News) -- More ... lowers hormone levels in postmenopausal women and provides protection ... Hope cancer center in Duarte, Calif. , Because studies ... enzyme that helps in estrogen production, the researchers looked ...
... Operational Expense For The Quarter Was $4.9 Million ... (Nasdaq: PCYC ) today reported financial ... 31, 2009. The net loss for the third ... $0.25 per share, compared to a net loss ...
Cached Medicine News:Health News:Reminder: Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium 2Health News:Reminder: Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium 3Health News:Reminder: Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium 4Health News:Proposed $350 Million Class Action Settlement Regarding Drug Pricing Provides Consumers and Third-Party Payors With Money Back 2Health News:For ST-Elevation Myocardial Infarction (STEMI), Interviewed Experts Indicate That The Medicines Company's Angiomax/Angiox Has Efficacy Advantages Over Sales-Leading ReoPro 2Health News:For ST-Elevation Myocardial Infarction (STEMI), Interviewed Experts Indicate That The Medicines Company's Angiomax/Angiox Has Efficacy Advantages Over Sales-Leading ReoPro 3Health News:Lamas Beauty International Announces Agreement With Macy's 2Health News:Lamas Beauty International Announces Agreement With Macy's 3Health News:No Verdict Yet on Grape Seed Extract vs. Breast Cancer 2Health News:Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results 2Health News:Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results 3Health News:Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results 4Health News:Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results 5Health News:Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results 6
... Universal Biomedical Amplifier (UBA-4204) from ... DC signal amplification and complete ... seen amplifier problems of DC ... These features make the amplifier ...
... The PACHETT 3 uses the exact ... all the DGH pachymeters used exclusively by ... is built into the software. The new ... measurements, running average, standard deviation and IOP ...
Orbital Retractor, schepens Retractors, overall length:154mm....
Stainless Steel. Box of 1, non sterile...
Medicine Products: